STAT3 and metabolic dysfunction-associated steatohepatitis: Moreover, we predicted that narcissin from BR, casuarictin from PRA, and γ-sitosterol from BR and ZRR, are the active compounds in XYS responsible for its therapeutic effect on NASH-related liver fibrosis, through targeting STAT3, NFκB, and PPARγ, respectively.